Researchers at BIDMC found in a national data analysis that over half of US adults, totaling 137 million, are eligible for semaglutide for weight loss, diabetes management, or preventing recurrent cardiovascular events. The study, published in JAMA Cardiology, emphasizes the need for improved access to this medication as its use is likely to increase in the future. Semaglutide is currently approved for various conditions like diabetes and obesity, with emerging data suggesting effectiveness for additional health issues, leading to potential growth in its use. The researchers highlight the importance of addressing economic barriers to access this transformative medication for population health.
Source link
More than half of US adults could benefit from GLP-1 medications, researchers find
